Remescor is an Advanced therapy medicinal products (ATMP) developed for human use that is based on mesenchymal stromal cells isolated from the umbilical cord (UC MSC). While many approaches are being investigated, mesenchymal stem cells are showing intriguing potential for the treatment of COVID-19 via modulation of immunological dysregulation and inflammation. According to European Medicinal Agency (EMA)somatic-cell therapy medicines these contain cells or tissues that have been manipulated to change their biological characteristics of cells or tissues not intended to be used for the same essential functions in the body (cure, diagnose or prevent diseases). Remescor® is a commercial name of a ATMP medicine based on the human umbilical cord-derived mesenchymal stromal cells.
Remescor® has been developed under the collaborative project between PrimeCell Advanced Therapy and Fakultní nemocnice u sv. Anny v Brně (FNUSA-ICRC) entitled “Development of regenerative and advanced therapy medicinal products based on cultured mesenchymal stem cells from umbilical cord” („Vývoj regenerativních a léčivých přípravků moderní terapie na bázi kultivovaných mesenchymálních kmenových buněk z tkáně pupečníku“) granted by the Technical Agency of the Czech Republic under the DELTA program (TF03000037). Results of the research have been published in the international peer-reviewed journal (https://doi.org/10.1007/s11064-019-02925-y). Currently, the results of basic research have been validated within the GMP facility (NATIC) of the manufacturer and new facility is under preparation for a scale-up of production capacity.
Pharmaceutical documentation has been submitted to SUKL (24. 3. 2020).
Publications:
Ladislava Vymetalova1 · Tereza Kucirkova1 · Lucia Knopfova1 · Veronika Pospisilova2,3 · Tomas Kasko2,3 ·
Hana Lejdarova4 · Eva Makaturova5 · Petr Kuglik5,6 · Veronika Oralova7 · Eva Matalova7 · Petr Benes1 · Zdenek Koristek2,8 · Serhiy Forostyak2,3,8
Large‑Scale Automated Hollow‑Fiber Bioreactor Expansion of Umbilical Cord‑Derived Human Mesenchymal Stromal Cells for Neurological Disorders 2018. Neurochemical Research.
Published: 2020
